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The central aspect of all quality
assurance programs in radiotherapy is to
guarantee the prescribed dose and dose
distribution in every treated patient. This should
assure as much as possible benefit from the
intended treatment and should also facilitate the
comparison of treatment results of multicentrical
studies. It is the topic of this paper to summarize
the special aspects of quality assurance in total
body irradiation prior to bone marrow
transplantation.
In general radiotherapy is an
interdisciplinary task and especially this is true for
total body irradiation. Many factors influence the
clinical outcome of this combined treatment
modality and their interaction is by far not well
understood.
Quality assurance in total body irradiation
covers all steps of this complex treatment
regiment inclUding clinical diagnosis, formulation
of the therapeutical concept, clinical and physical
treatment planning, desimetry, and treatment
verification. A clear dose prescription
is a prerequisite for all following steps in total
body irradiation. This is not self-evident and
contrasts with more conventional radiation
therapy treatment situations because of the
complex target volume.
Localization/simulation as the essential
part of clinical treatment planning consists
mainly in delineating the lung areas to be
shielded in order to protect the most critical
organ at risk. The requirements on dosimetry
and physical treatment planning are outlined
including the possibilities and limitations of
commercially available therapy planning
systems for total body irradiation. Treatment
verification procedures comprise the control of
the different treatment parameters like patient
position, alignment of shielding blocks and
compensators or boli and machine settings.
This is similiar to the situation in conventional
radiotherapy. Besides this the distinctive
importance of in vivo dosimetry for quality
assurance in total body irradiation will
be outlined.
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The treatment of women with advanced
cervical carcinoma consist in the irradiation of
the pelVis. The irradiated area includes tumor
together with adjacent organs (bladder, rectum).
Because of its immediate prOXimity to the tumor
the bladder is particularly exposed to X-rays and
is a critical organ in this therapy.We calculated
the total dose from brachy and teletherapy in
women with advanced cervical cancer using the
Target 2 Plus system. The reference points in
the pelvis were determined according to the
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ICRU-38 report. The doses from teletherapy
were 40-44 Gy, from brachytherapy 50-55 Gy in
the reference points. The total doses received
by the bladder in both parts of the treatment
reached 40-75 Gy in the poins of maximum
exposure.The doses received by the remaining
parts of the organ were significantly lower.
Determinig the total dose makes it possible to
modify the dose in the bladder and to prevent
possible complications.
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